| Sub Cat | Epitope | |
|---|---|---|
| V3S-1124-YC2250 | Omi-42 does not contact either of the two BA.4/5 mutation sites. | |
| V3S-0523-XY35 | Analysis of HIV-1 pseudotypes with these mutations confirmed that D420Y, N460H, L455R and Y453H alone each abolished the weak C098 neutralization activity | |
| V3S-0523-XY36 | D420Y, N460Y, or L455R single mutants with partial (10-fold or less) C099 resistance. D420Y/N460H and L455R/Y453H double mutants with higher levels of C099-resistance (~100-fold). | |
| V3S-0523-XY37 | The antibody associates with the RBD through a similar binding mode to bridge adjacent RBDs on the surface of the S trimer. Mutations at RBD positions L455, F456, E484, and Q493 conferred escape from the mAb. | |
| V3S-0523-XY38 | The antibody mediated the majority of RBD contacts. Mutations at RBD position E484K conferred escape from C051. | |
| V3S-0523-XY40 | Mutations at positions R346, N439, N440, K444, V445 and G446 all conferred resistance to C032. |
| Description | This product is a neutralizing antibody that binds to Severe Acute Respiratory Syndrome Coronavirus 2. Omi-42 is capable of specifically binding with SARS-CoV-2 and shows a good capacity to neutralize the SARS-CoV-2. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Epitope | Omi-42 does not contact either of the two BA.4/5 mutation sites. |
| Isotype | IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
